Phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma

被引：0
|
作者：
Fox, E.
Widemann, B. C.
Whitcomb, P. O.
Aikin, A.
Dombi, E.
Lodish, M.
Stratakis, C. A.
Steinberg, S.
Wells, S. A., Jr.
Balis, F. M.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NICHD, Bethesda, MD USA
[3] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10014
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Management of hereditary medullary thyroid carcinoma
    Theodora Pappa
    Maria Alevizaki
    Endocrine, 2016, 53 : 7 - 17
  • [22] SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY
    Uchino, Keita
    Komoda, Masato
    Tomomatsu, Junichi
    Okamoto, Takahiro
    Horiuchi, Kiyomi
    Tsuji, Akihito
    Ito, Yasuhiro
    Todo, Takuya
    Rito, Ki
    Takahashi, Shunji
    ENDOCRINE PRACTICE, 2017, 23 (02) : 149 - 156
  • [23] Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma
    Kothari, Ronik
    Kreimer, Sara
    Nadel, Helen
    Seeley, Hilary
    Hartman, Gary
    Meister, Kara D.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [24] CLINICOPATHOLOGICAL FEATURES OF MEDULLARY-THYROID CARCINOMA IN CHILDREN AND ADOLESCENTS
    RAJU, U
    KINI, S
    JACKSON, CE
    LABORATORY INVESTIGATION, 1988, 58 (01) : P7 - P7
  • [25] CLINICOPATHOLOGICAL FEATURES OF MEDULLARY-THYROID CARCINOMA IN CHILDREN AND ADOLESCENTS
    RAJU, U
    KINI, S
    JACKSON, CE
    MODERN PATHOLOGY, 1988, 1 (01) : P7 - P7
  • [26] Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Wells, Samuel A., Jr.
    Gosnell, Jessica E.
    Gagel, Robert F.
    Moley, Jeffrey
    Pfister, David
    Sosa, Julie A.
    Skinner, Michael
    Krebs, Annetta
    Vasselli, James
    Schlumberger, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) : 767 - 772
  • [27] A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer.
    Wells, S.
    You, Y. N.
    Lakhani, V.
    Hou, J.
    Langmuir, P.
    Headley, D.
    Skinner, M.
    Morse, M.
    Burch, W.
    Schlumberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 288S - 288S
  • [28] Molecular mechanism(s) of resistance to vandetanib in medullary thyroid carcinoma.
    Glassberg, Brittany
    Khan, Sophia
    Pemov, Alex
    Hawley, Robert
    Widemann, Brigitte C.
    Khan, Javed
    Glod, John
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
    Durante, Cosimo
    Paciaroni, Alessandra
    Plasmati, Katia
    Trulli, Fabiana
    Filetti, Sebastiano
    ENDOCRINE, 2013, 44 (02) : 334 - 342
  • [30] A phase I/II trial of vandetanib for patients with recurrent malignant glioma
    Kreisl, Teri N.
    McNeill, Katharine A.
    Sul, Joohee
    Iwamoto, Fabio M.
    Shih, Joanna
    Fine, Howard A.
    NEURO-ONCOLOGY, 2012, 14 (12) : 1519 - 1526
12345